|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2024-01-18 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2023-11-16 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2022-10-31 |
A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)
100 项与 AstraZeneca Korea Ltd. 相关的临床结果
0 项与 AstraZeneca Korea Ltd. 相关的专利(医药)
100 项与 AstraZeneca Korea Ltd. 相关的药物交易
100 项与 AstraZeneca Korea Ltd. 相关的转化医学